How to Reverse Digoxin Toxicity: Antidote and Care

Digoxin-specific antibody fragments, sold under brand names like DigiFab, are the definitive antidote for digoxin toxicity and can reverse life-threatening arrhythmias within minutes. But the antidote is only one piece of a broader management picture that includes electrolyte correction, bridging medications, careful monitoring for rebound toxicity, and awareness of diagnostic pitfalls that can trip up even experienced clinicians.

How Digoxin Becomes Toxic

Digoxin works by partially blocking a pump on heart muscle cells called the sodium-potassium ATPase. When that pump is inhibited, sodium builds up inside the cell, which in turn causes calcium to accumulate. The extra calcium is what makes the heart squeeze harder, which is the whole therapeutic point of the drug. But when digoxin levels climb too high, that calcium overload becomes dangerous, triggering electrical instability in the heart.¹

Toxicity can happen in two distinct ways. Acute poisoning occurs when someone takes a large single dose, whether intentionally, accidentally, or from ingesting a plant like foxglove or oleander that contains similar compounds.² Chronic toxicity, which accounts for the majority of digoxin poisonings, develops gradually in patients already taking the drug, often because something changes: kidney function declines, an interacting medication is added, or electrolytes drift out of range.³ Chronic toxicity is actually harder to manage than acute overdose because the symptoms can be subtler and the patient often has underlying heart disease that complicates the picture.

Recognizing Digoxin Toxicity

The symptoms tend to follow a pattern, though acute and chronic poisoning do not look identical. Nausea, vomiting, and loss of appetite are among the earliest signs in both forms. Visual disturbances, classically described as seeing yellow-green halos around lights, are a well-known clue, though they are not present in every case. Confusion, fatigue, and generalized weakness are common in chronic toxicity, especially in elderly patients who may already have some cognitive decline that masks the change.

The most dangerous manifestations are cardiac. Disturbances in how electrical signals travel through the heart, including slowed conduction through the AV node and various degrees of heart block, occur in both acute and chronic poisoning. Ventricular ectopy, where the lower chambers of the heart fire off extra beats on their own, is particularly common in the chronic form.⁴ One hallmark rhythm that should raise immediate suspicion is bidirectional ventricular tachycardia, a rare arrhythmia where the shape of the heartbeat alternates back and forth on the ECG. It was first described in a patient with digitalis poisoning over a hundred years ago and remains strongly associated with this diagnosis.⁵

The Antidote and When It Is Indicated

Digoxin immune Fab is made from antibody fragments (derived from sheep) that bind free digoxin in the bloodstream. Once bound, the digoxin molecule can no longer attach to the sodium-potassium pump on heart cells, and the digoxin-Fab complex is gradually cleared by the kidneys.⁶ The effect can be remarkably fast, with rhythm disturbances often improving within 30 minutes of infusion.

Not every elevated digoxin level requires the antidote. The decision to give immune Fab depends on clinical severity, not just a number on a lab report. That said, there are widely accepted thresholds that trigger its use:

Life-threatening arrhythmia: any digoxin-related rhythm disturbance that is hemodynamically unstable, regardless of the serum level.
Severe hyperkalemia: serum potassium above 5.5 mEq/L in the setting of acute digoxin poisoning.
Very high serum levels: digoxin concentration above 15 ng/mL at any time, or above 10 ng/mL when measured six or more hours after acute ingestion.
Large acute ingestion: more than 10 mg in an adult or more than 4 mg in a child.
Critically unstable patient: empiric dosing even before lab confirmation in a patient with a clinical picture consistent with digoxin poisoning.

These indications apply to both pharmaceutical digoxin and plant-derived cardiac glycoside poisonings, since the antibody fragments can bind to related compounds found in foxglove, oleander, and similar plants.⁷

A large observational study of patients treated with digoxin immune Fab found that half had a complete response and another quarter had a partial response. Allergic reactions were uncommon, occurring in fewer than one percent of cases.⁸ The twelve percent who showed no response likely had irreversible cardiac damage or co-existing conditions beyond the reach of the antidote.

Bridging Treatments When Fab Is Not Immediately Available

Digoxin immune Fab is not always stocked in every emergency department, and even when it is, there may be a delay while pharmacy prepares the infusion. During that gap, clinicians rely on other medications to stabilize the patient.

For fast, dangerous heart rhythms originating in the ventricles, intravenous lidocaine or magnesium sulfate can help suppress the arrhythmia. Magnesium is considered particularly useful because it can be given even when serum magnesium levels are already elevated.⁹ For dangerously slow heart rates, atropine is the first-line agent. Drugs like adrenaline (epinephrine) and isoprenaline (isoproterenol) should be avoided because they can push an already irritable heart into ventricular fibrillation. Temporary cardiac pacing may be needed in some cases, though expert consensus recommends it be handled only by experienced teams because pacing wires in the setting of a digoxin-toxic heart can themselves trigger lethal rhythms.¹⁰

The Potassium Problem

Potassium sits at the center of digoxin toxicity in a way that can be genuinely confusing, because both too much and too little potassium can make things worse, and the clinical situation differs between acute and chronic poisoning.

In acute digoxin overdose, the massive blockade of the sodium-potassium pump prevents potassium from entering cells, so serum potassium rises. That hyperkalemia is itself a major danger and one of the criteria for giving immune Fab immediately. In chronic toxicity, the picture is often the opposite: patients on digoxin are frequently also taking diuretics that deplete potassium. Low potassium makes heart cells more sensitive to digoxin’s toxic effects, so even a therapeutic digoxin level can become toxic in the setting of hypokalemia. Historically, some guidelines recommended giving potassium to patients with chronic digoxin toxicity, even when their levels were in the normal range, as a way to protect against arrhythmias.

That recommendation now carries a caution. A case-control study of chronic digoxin toxicity patients found that hyperkalemia, far from being protective, was associated with an 86% mortality rate even when patients received appropriate doses of immune Fab.¹¹ So while correcting low potassium remains important, overshooting into high potassium is dangerous. Careful monitoring is essential, and potassium supplementation should be guided by serial lab measurements rather than given empirically without checking levels.

The Calcium Controversy

For decades, textbooks taught that intravenous calcium should never be given to a patient with digoxin toxicity. The reasoning seemed logical: digoxin toxicity is caused by calcium overload inside heart cells, so adding more calcium to the bloodstream could theoretically push cells over the edge into fatal arrhythmias. The concept was often described as “stone heart,” implying that the combination would cause irreversible cardiac standstill.

The evidence tells a more nuanced story. A retrospective study that specifically examined digoxin-toxic patients who received intravenous calcium found no life-threatening arrhythmias within an hour of calcium administration. Mortality was similar between patients who received calcium (about 22%) and those who did not (about 20%). If anything, the statistical analysis suggested a slight, non-significant trend toward lower odds of death in the calcium group.¹² This does not mean calcium is recommended, but it does suggest the traditional prohibition may have been overly rigid. In practice, the current consensus is to avoid calcium unless there is a compelling separate indication, such as dangerously high potassium where calcium is needed to protect the heart while definitive treatment is arranged.

Why Digoxin Levels Become Unreadable After Treatment

One of the most underappreciated pitfalls in managing digoxin toxicity comes after the antidote has been given. Standard laboratory assays measure all digoxin in the blood, both free (active) and Fab-bound (inactive). After immune Fab administration, the total digoxin concentration measured by the lab can spike dramatically, sometimes to alarming levels, even though the clinically active fraction has dropped. This happens because Fab pulls digoxin out of tissues and into the bloodstream where it is bound and harmless, but the assay cannot tell the difference.¹³

Different assay methods can give wildly different results in the same blood sample. Clinicians who are not aware of this can mistakenly give additional Fab doses based on a lab number that does not reflect clinical reality, or they can panic about a sky-high reading when the patient is actually improving.¹⁴ The practical takeaway is that after Fab treatment, clinical assessment matters far more than lab numbers. If the patient’s rhythm has improved and symptoms are resolving, a high total digoxin level should not prompt alarm or additional treatment.

Rebound Toxicity After the Antidote Wears Off

The Fab-digoxin complex is cleared by the kidneys, and in a patient with normal kidney function, that clearance has a half-life of roughly 14 to 16 hours.¹⁵ The problem is that many patients who develop digoxin toxicity, particularly the chronic form in elderly patients, have impaired kidneys. When the kidneys cannot clear the Fab-digoxin complex efficiently, the complex lingers in the body and can eventually break apart, releasing free digoxin back into the bloodstream. This phenomenon is called rebound toxicity or recrudescent toxicity.

The observational surveillance study mentioned earlier found that roughly 3% of patients experienced rebound toxicity, and the risk jumped sixfold when patients received less than half the calculated dose of immune Fab.⁸ In patients with significant kidney impairment, the risk is higher and the monitoring window needs to be longer. Case reports describe patients whose symptoms and arrhythmias returned hours to days after initially responding to the antidote.¹⁶ These patients required additional doses of Fab.

A complicating factor is that digoxin-Fab complexes are not removed by standard hemodialysis, so dialysis alone cannot clear the drug in patients with kidney failure.¹⁷ Plasma exchange has been tried as a last resort in cases where kidney injury is severe and repeated Fab dosing is not controlling the toxicity, though evidence for this approach is limited to individual case reports.

Drug Interactions That Trigger Toxicity in the First Place

Many cases of chronic digoxin toxicity are preventable. Because digoxin has a narrow therapeutic window, relatively small changes in how the body handles the drug can tip levels into the dangerous range. Several commonly prescribed medications are known to raise digoxin levels substantially. Quinidine and amiodarone, both antiarrhythmic drugs, can markedly increase steady-state digoxin concentrations. Verapamil, a calcium channel blocker, has a similar effect. Spironolactone, a potassium-sparing diuretic, can alter how digoxin is handled by the kidneys.¹⁸

Beyond prescription medications, worsening kidney function from any cause, including dehydration, new medications, or the progression of chronic kidney disease, will reduce digoxin clearance and raise blood levels. Loop diuretics like furosemide, while they do not directly raise digoxin levels, can cause potassium and magnesium depletion that sensitizes the heart to digoxin’s toxic effects. This is why patients on long-term digoxin therapy need regular monitoring of both drug levels and electrolytes, especially after any change in their medication regimen or health status.

False Readings in Patients Not Taking Digoxin

An odd footnote in digoxin monitoring is the existence of endogenous digoxin-like immunoreactive substances, naturally occurring compounds in the body that can cross-react with laboratory digoxin assays and produce false-positive readings. These substances have been found at meaningful levels in pregnant women, newborns, patients with kidney failure, and people with liver disease.¹⁹ In cord blood from newborns, apparent digoxin levels as high as 1.1 micrograms per liter have been measured in infants who had no exposure to the drug whatsoever.²⁰

This matters for two reasons. First, a patient in one of these groups who is genuinely on digoxin may have a falsely elevated level that leads to unnecessary alarm or unwarranted treatment changes. Second, a patient not on digoxin at all may get a positive reading that confuses the clinical picture, for instance, a pregnant woman or a dialysis patient who presents with an arrhythmia and has a “positive” digoxin level. Different assay platforms have different degrees of cross-reactivity with these endogenous substances, and newer turbidimetric assays are somewhat less susceptible. Still, clinicians need to be aware that a digoxin level is not always what it appears to be, particularly in these vulnerable populations.

Plant-Derived Cardiac Glycoside Poisoning

Digoxin was originally derived from the foxglove plant, and many plants around the world contain related cardiac glycosides that act on the same sodium-potassium pump. Foxglove itself is the most commonly reported source of accidental plant-based poisoning in temperate climates. Its leaves can be mistaken for comfrey or other edible greens, and even a small amount can cause serious toxicity. Oleander, lily of the valley, and certain toad species also contain cardiac glycosides that produce a clinical picture virtually identical to digoxin poisoning.²

The management principles are the same as for pharmaceutical digoxin toxicity: immune Fab is the antidote, supportive care addresses the immediate arrhythmia risk, and electrolyte management is critical. One wrinkle is that serum digoxin assays may not detect plant-derived glycosides at all, or may detect them with varying and unreliable sensitivity. A patient who has eaten foxglove may have a clinical picture screaming digoxin toxicity but a digoxin level that reads as zero. In these situations, the clinical presentation dictates treatment. Lab confirmation is helpful when it is positive, but a negative level should never be used to withhold immune Fab from a patient with a convincing history and exam.

The Fab fragments themselves have higher binding affinity for digoxin than for some of the plant-derived glycoside variants, so higher doses may be needed for plant poisoning compared with the same severity of pharmaceutical digoxin overdose.⁶ Treatment in these cases is often empiric, starting with a standard dose and titrating to clinical response, because there is no reliable way to quantify how much glycoside the patient absorbed from the plant material.